Skip to main content

Astrazeneca PLC 6-K, filed Nov 16, 2026

Astrazeneca PLC (AZN)

6-K 2026-11-16 For: 2026-11-16
View Original
Added on November 16, 2026

About this 6-K

Astrazeneca PLC filed this 6-K on November 16, 2026.

AstraZeneca PLC reported that Klygefa (gefurulimab) received European Union (EU) approval as an add-on to standard therapy for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis, based on positive PREVAIL Phase III trial results. AI summary